Literature DB >> 16996408

Early mitochondrial dysfunction in an infant with Alexander disease.

Cristina Cáceres-Marzal1, Julián Vaquerizo, Enrique Galán, Santiago Fernández.   

Abstract

Alexander disease is a neurodegenerative disorder characterized by macrocephaly and progressive demyelination with frontal lobe preponderance. The infantile form, the most frequent variant, appears between birth and 2 years of age and involves a severe course with a rapid neurologic deterioration. Although magnetic resonance imaging is useful for diagnosis, currently diagnosis is confirmed by the finding of missense mutation in the glial fibrillary acidic protein (GFAP) gene. This case reports a female who presented at the age of 5 months with refractory epilepsy and hypotonia. Laboratory examinations, muscle biopsy examination, and energetic metabolic study in muscle indicated increased concentrations of lactate, mitochondria with structural abnormalities, and decreased cytochrome-c oxidase activity respectively. Later, both clinical course and magnetic resonance findings were compatible with Alexander disease, which was confirmed by the finding of a novel glial fibrillary acidic protein gene mutation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16996408     DOI: 10.1016/j.pediatrneurol.2006.03.010

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  6 in total

1.  Alexander disease causing mutations in the C-terminal domain of GFAP are deleterious both to assembly and network formation with the potential to both activate caspase 3 and decrease cell viability.

Authors:  Yi-Song Chen; Suh-Ciuan Lim; Mei-Hsuan Chen; Roy A Quinlan; Ming-Der Perng
Journal:  Exp Cell Res       Date:  2011-07-02       Impact factor: 3.905

Review 2.  GFAP and its role in Alexander disease.

Authors:  Roy A Quinlan; Michael Brenner; James E Goldman; Albee Messing
Journal:  Exp Cell Res       Date:  2007-04-06       Impact factor: 3.905

3.  Chaperone-independent mitochondrial translocation and protection by αB-crystallin in RPE cells.

Authors:  Rebecca S McGreal; Lisa A Brennan; Wanda Lee Kantorow; Jeffrey D Wilcox; Jianning Wei; Daniel Chauss; Marc Kantorow
Journal:  Exp Eye Res       Date:  2013-03-04       Impact factor: 3.467

4.  GFAP mutations, age at onset, and clinical subtypes in Alexander disease.

Authors:  M Prust; J Wang; H Morizono; A Messing; M Brenner; E Gordon; T Hartka; A Sokohl; R Schiffmann; H Gordish-Dressman; R Albin; H Amartino; K Brockman; A Dinopoulos; M T Dotti; D Fain; R Fernandez; J Ferreira; J Fleming; D Gill; M Griebel; H Heilstedt; P Kaplan; D Lewis; M Nakagawa; R Pedersen; A Reddy; Y Sawaishi; M Schneider; E Sherr; Y Takiyama; K Wakabayashi; J R Gorospe; A Vanderver
Journal:  Neurology       Date:  2011-09-14       Impact factor: 11.800

5.  Respiratory chain deficiency in nonmitochondrial disease.

Authors:  Angela Pyle; Helen J Nightingale; Helen Griffin; Angela Abicht; Janbernd Kirschner; Ivo Baric; Mario Cuk; Konstantinos Douroudis; Lea Feder; Markus Kratz; Birgit Czermin; Stephanie Kleinle; Mauro Santibanez-Koref; Veronika Karcagi; Elke Holinski-Feder; Patrick F Chinnery; Rita Horvath
Journal:  Neurol Genet       Date:  2015-04-27

6.  Tissue and cellular rigidity and mechanosensitive signaling activation in Alexander disease.

Authors:  Liqun Wang; Jing Xia; Jonathan Li; Tracy L Hagemann; Jeffrey R Jones; Ernest Fraenkel; David A Weitz; Su-Chun Zhang; Albee Messing; Mel B Feany
Journal:  Nat Commun       Date:  2018-05-15       Impact factor: 14.919

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.